Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Well Differentiated Pancreatic Endocrine Tumor
|
3 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||
Tumor Progression
|
72 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.030 | 1.000 | 3 | 2004 | 2015 | ||||
Stomach Carcinoma
|
652 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.020 | 0.500 | 2 | 2010 | 2013 | ||||
Squamous cell carcinoma of oropharynx
|
33 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Squamous cell carcinoma of mouth
|
1 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||
Squamous cell carcinoma
|
257 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.020 | 1.000 | 2 | 2010 | 2017 | ||||
Secondary malignant neoplasm of lymph node
|
188 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||
Sarcoma of soft tissue
|
6 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||
Sarcoma
|
42 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||
Prostate carcinoma
|
1168 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.080 | 0.875 | 8 | 2005 | 2017 | ||||
Progression of prostate cancer
|
7 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2008 | 2008 | ||||
Primary malignant neoplasm of lung
|
981 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.030 | 1.000 | 3 | 2007 | 2017 | ||||
Primary malignant neoplasm
|
1374 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.100 | 0.909 | 11 | 2005 | 2017 | ||||
Pituitary-dependent Cushing's disease
|
8 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||
Oropharynx (excludes nasopharynx)
|
5 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||
Non-Small Cell Lung Carcinoma
|
712 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||
Node-positive breast cancer
|
3 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.020 | 1.000 | 2 | 2006 | 2015 | ||||
Neuroendocrine Tumors
|
20 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Neoplasms
|
1644 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.040 | 0.500 | 4 | 2010 | 2013 | ||||
Neoplasm Metastasis
|
327 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.020 | 0.500 | 2 | 2012 | 2017 | ||||
Malignant tumor of cervix
|
245 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||
Malignant Neoplasms
|
1641 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.100 | 0.917 | 12 | 2005 | 2017 | ||||
Malignant neoplasm of urinary bladder
|
316 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.010 | 1.000 | 1 | 2006 | 2006 | ||||
Malignant neoplasm of stomach
|
615 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.020 | 0.500 | 2 | 2010 | 2013 | ||||
Malignant neoplasm of prostate
|
1082 | 0.597 | 0.560 | 5 | 177093242 | missense variant | G/A | snv | 0.33 | 0.26 | 0.780 | 0.900 | 10 | 2005 | 2017 |